Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

NCT05150587 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

216

Enrollment

INDUSTRY

Sponsor class

Conditions

Papulopustular Rosacea

Interventions

DRUG: Rifaximin
DRUG: Placebo

Sponsor

Alfasigma S.p.A.

Collaborators

[object Object]